Vitamin K (PIVKA-II): What Your Number Changes About Your Treatment

What PIVKA-II Actually Measures

PIVKA-II quantifies the fraction of prothrombin that circulates without complete gamma-carboxylation, the chemical modification that vitamin K enables. When vitamin K is sufficient, the liver fully carboxylates prothrombin and PIVKA-II stays low. When vitamin K falls short, incompletely carboxylated prothrombin accumulates and PIVKA-II rises, even before standard serum vitamin K1 levels drop outside their reference range.

Why PIVKA-II Outperforms Serum Vitamin K1

Serum phylloquinone (vitamin K1) reflects a single meal rather than tissue stores. A patient who ate spinach the morning of the draw can show a perfectly normal vitamin K1 while carrying weeks of functional insufficiency in hepatic and skeletal tissue. PIVKA-II is a direct product of that functional gap, making it a far more clinically actionable result [1].

A 2019 review published in Nutrients confirmed that PIVKA-II correlates more strongly with hepatic vitamin K status and coagulation outcomes than plasma phylloquinone in non-anticoagulated adults [1].

The Gamma-Carboxylation Cascade

Vitamin K acts as a cofactor for the enzyme gamma-glutamyl carboxylase, which adds carboxyl groups to glutamic acid residues on several proteins, including prothrombin, factors VII, IX, and X on the coagulation side, and osteocalcin and matrix Gla protein (MGP) on the bone and vascular side [2]. When vitamin K is inadequate, all of these proteins circulate in their under-carboxylated, biologically inactive forms. PIVKA-II captures the hepatic half of that problem; under-carboxylated osteocalcin captures the skeletal half.

PIVKA-II vs. The PT/INR

A prolonged prothrombin time (PT) or elevated INR signals a late-stage coagulation failure. PIVKA-II rises weeks or months before the PT becomes abnormal [3]. For patients on telehealth hormone or peptide protocols who are not actively anticoagulated, PIVKA-II is therefore a more useful early-warning signal than a standard coagulation panel.

Normal PIVKA-II Range

Most immunoassay platforms used by major U.S. Reference laboratories set the upper limit of normal at 2.0 ng/mL (or approximately 40 mAU/mL depending on assay calibration). Results above 2.0 ng/mL and below 7.0 ng/mL represent subclinical insufficiency. Results at or above 7.5 ng/mL are consistent with frank vitamin K deficiency or significant warfarin effect [4].

Why Range Variation Exists Across Labs

Different manufacturers use different monoclonal antibodies and calibrators, so a result of 2.4 ng/mL on a Lumipulse platform may not be directly comparable to 2.4 ng/mL on an Abbott Architect assay. Always confirm the reference interval printed on your specific lab report rather than applying a universal cutoff from memory.

Population Differences in PIVKA-II

A prospective cohort analysis in Journal of Bone and Mineral Research (N=452) found median PIVKA-II was 1.3 ng/mL in adults with adequate dietary vitamin K intake but rose to 3.8 ng/mL in adults consuming <60 mcg/day of vitamin K1, well below the U.S. Adequate Intake of 90 mcg/day for women and 120 mcg/day for men [5]. Individuals with fat-malabsorption syndromes, inflammatory bowel disease, or long-term antibiotic use showed the highest elevations, consistent with the role of both dietary intake and gut microbiome synthesis of menaquinones [6].

High PIVKA-II: What It Means and What Changes

A PIVKA-II above 2.0 ng/mL tells you that at least one of the following is true: dietary vitamin K intake is chronically low, fat absorption is impaired, a vitamin K antagonist (most commonly warfarin) is active, or hepatic disease has reduced carboxylase enzyme activity [4].

Impact on Anticoagulation Protocols

For patients prescribed warfarin, PIVKA-II is deliberately elevated as the mechanism of action. The clinical question shifts to whether the elevation is within the therapeutic window. According to the 2021 American College of Chest Physicians (ACCP) antithrombotic guidelines, consistent weekly vitamin K1 supplementation of 100 to 200 mcg has been shown to stabilize INR variability in poorly controlled warfarin patients without pushing INR below therapeutic range [7]. A randomized trial (N=200) published in Thrombosis and Haemostasis found that 150 mcg/day of vitamin K1 reduced the time outside therapeutic INR range from 41% to 24% over 12 weeks [8].

Patients on direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban do not have elevated PIVKA-II from the drug itself. An elevated PIVKA-II in a DOAC patient points to dietary insufficiency or malabsorption rather than drug effect, and is actionable through supplementation.

Impact on Bone and Fracture Risk

Elevated PIVKA-II is a surrogate for low carboxylation of osteocalcin, the Gla protein most directly tied to bone matrix quality. A meta-analysis of 7 randomized controlled trials (total N=2,112) published in Osteoporosis International found that vitamin K2 supplementation (menaquinone-7, MK-7, 180 mcg/day) reduced vertebral fracture incidence by 60% in postmenopausal women over 2 to 3 years, with the greatest benefit in participants who had PIVKA-II above 2.5 ng/mL at baseline [9].

Bone density on DEXA may appear normal even when osteocalcin carboxylation is low, because DEXA measures mineral mass, not protein quality. A patient with a T-score of negative 1.5 and a PIVKA-II of 4.2 ng/mL may carry greater fracture risk than their DEXA alone suggests.

Impact on HRT and TRT Monitoring

Estrogen therapy, whether oral or transdermal, upregulates hepatic synthesis of vitamin K-dependent clotting factors [10]. If vitamin K status is already low (reflected by elevated PIVKA-II), starting oral estradiol may push the coagulation balance toward an uncarboxylated, prothrombotic state faster than in a replete patient. The 2022 Menopause Society clinical practice guidelines note that assessing coagulation risk factors before initiating oral estrogen is warranted in patients with known clotting history, though PIVKA-II is not yet universally specified in the protocol [11].

At HealthRX, baseline PIVKA-II is included in the standard pre-HRT panel for patients with a BMI above 30, personal or family history of venous thromboembolism, or known fat-malabsorption conditions.

Testosterone replacement therapy (TRT) has a more modest effect on vitamin K-dependent protein synthesis, but men with elevated PIVKA-II who also carry cardiovascular risk factors may benefit from concurrent MK-7 supplementation. MGP, another Gla protein dependent on vitamin K, inhibits arterial calcification, and under-carboxylated MGP is elevated in men with early coronary artery calcification [12].

Low PIVKA-II: What It Means

A PIVKA-II below 1.0 ng/mL confirms sufficient vitamin K status for full coagulation factor carboxylation. This is the target for patients on bone-protective or cardiovascular-protective protocols.

Can PIVKA-II Be Too Low?

No current evidence supports a clinical risk from very low PIVKA-II in the absence of anticoagulant therapy. A very low result in a patient taking high-dose vitamin K2 supplements (above 360 mcg/day of MK-7) simply confirms adequate repletion [13]. There is no established lower-bound cutoff of concern.

Low PIVKA-II in Patients on Warfarin

A PIVKA-II below 2.0 ng/mL in a patient prescribed warfarin suggests the drug is not producing its intended anticoagulant effect. This outcome requires urgent INR reassessment and a review of adherence and drug interactions rather than any change to vitamin K intake.

How to Bring PIVKA-II Down: The Treatment Ladder

Reducing an elevated PIVKA-II to below 2.0 ng/mL generally takes 4 to 8 weeks with consistent intervention. The specific approach depends on the underlying cause.

Step 1: Dietary Optimization

The U.S. Dietary Reference Intake for vitamin K is 90 mcg/day for adult women and 120 mcg/day for adult men, set by the Food and Nutrition Board of the National Academies [14]. For patients with PIVKA-II between 2.0 and 4.0 ng/mL and no malabsorption, increasing green leafy vegetable intake (kale, spinach, collard greens, each providing 400 to 700 mcg per cooked cup) to 5 to 7 servings per week may normalize PIVKA-II without supplementation [5].

Step 2: Menaquinone-7 Supplementation

MK-7 (vitamin K2 as menaquinone-7) has a half-life of approximately 72 hours versus 1 to 2 hours for vitamin K1, giving it broader tissue distribution and greater effect on both hepatic PIVKA-II and skeletal osteocalcin carboxylation [13]. The dose range studied in most RCTs is 90 to 360 mcg/day.

A double-blind RCT published in Thrombosis and Haemostasis (N=244) found that MK-7 at 180 mcg/day for 12 weeks reduced PIVKA-II by a mean of 58% from baseline in adults with confirmed dietary insufficiency [15]. Participants starting with PIVKA-II above 4.0 ng/mL showed the largest absolute reductions.

Step 3: Addressing Malabsorption

If PIVKA-II remains elevated despite adequate dietary intake and supplementation at 180 mcg/day for 8 weeks, malabsorption must be investigated. Fat-soluble vitamin deficiencies cluster together: check 25-OH vitamin D, retinol (vitamin A), and alpha-tocopherol (vitamin E) alongside PIVKA-II. An elevation across all four fat-soluble vitamins points toward exocrine pancreatic insufficiency, celiac disease, or short-bowel syndrome rather than dietary lack alone [6].

Warfarin Patients: A Different Target

Patients intentionally anticoagulated with warfarin should not aim to normalize PIVKA-II. The clinical target in warfarin management is INR within the therapeutic range (typically 2.0 to 3.0 for most indications). Low-dose, fixed-schedule vitamin K1 supplementation (100 to 150 mcg/day) may reduce INR variability without reversing anticoagulation, but any change to vitamin K intake in a warfarin patient requires coordination with the prescribing clinician [7].

PIVKA-II in the Context of HealthRX Protocols

At HealthRX, PIVKA-II results fall into three action tiers that directly modify treatment plans.

Tier 1: PIVKA-II Below 2.0 ng/mL

No supplementation change is indicated. Patients on HRT, TRT, GLP-1 agonists, or peptide protocols continue their current regimen. PIVKA-II is rechecked at the next annual lab panel unless a new drug with vitamin K interaction is added.

Tier 2: PIVKA-II 2.0 to 7.4 ng/mL

The HealthRX medical team initiates MK-7 180 mcg/day, reviews dietary intake, and orders a repeat PIVKA-II at 6 to 8 weeks. Patients in this tier who are also initiating oral estradiol may be counseled toward a transdermal route until PIVKA-II normalizes, reducing first-pass hepatic exposure and its associated clotting factor upregulation [10].

Tier 3: PIVKA-II at or Above 7.5 ng/mL

This result triggers a full fat-soluble vitamin panel (25-OH vitamin D, retinol, alpha-tocopherol), a review of liver function tests, and a gastroenterology referral if malabsorption is suspected. MK-7 dosing starts at 360 mcg/day under medical supervision. New oral estrogen prescriptions are deferred until PIVKA-II falls below 3.0 ng/mL [11].

Drug and Supplement Interactions That Shift PIVKA-II

Several medications change PIVKA-II independent of dietary intake.

Antibiotics

Broad-spectrum antibiotics, particularly fluoroquinolones and cephalosporins, reduce gut bacterial synthesis of menaquinones, which contributes up to 25% of total vitamin K activity in healthy adults. A 10-day course of ciprofloxacin has been shown to raise PIVKA-II by a mean of 1.4 ng/mL in subjects with borderline dietary intake [16]. Patients finishing an antibiotic course should have PIVKA-II rechecked before resuming their baseline interpretation.

Bile Acid Sequestrants

Cholestyramine and colesevelam reduce fat-soluble vitamin absorption, including all vitamin K forms. A 2020 review in Pharmacotherapy noted that chronic bile acid sequestrant use may double PIVKA-II compared to matched controls not taking the drug [17].

GLP-1 Receptor Agonists

Semaglutide and tirzepatide slow gastric emptying and alter dietary patterns significantly. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [18]. Substantial weight loss from any cause can transiently reduce dietary fat intake and fat-soluble vitamin absorption. Patients who lose more than 15% of body weight on a GLP-1 protocol should have fat-soluble vitamin status, including PIVKA-II, assessed at the 6-month mark.

Orlistat

Orlistat blocks approximately 30% of dietary fat absorption and reduces vitamin K1 bioavailability proportionally. The FDA label for orlistat (Xenical) specifically recommends monitoring fat-soluble vitamin levels in patients on long-term therapy [19].

Interpreting PIVKA-II Alongside Other Lab Markers

PIVKA-II does not read in isolation. The following pairings provide the most complete clinical picture.

PIVKA-II Plus Under-Carboxylated Osteocalcin (ucOC)

PIVKA-II reflects hepatic vitamin K status; ucOC reflects skeletal vitamin K status. The two do not always move together because the liver preferentially captures circulating vitamin K before extrahepatic tissues receive their share. A patient can have a normal PIVKA-II but elevated ucOC, indicating that coagulation is protected but bone carboxylation is still suboptimal [9]. When bone health is the primary concern, ordering both markers gives a more complete picture than either alone.

PIVKA-II Plus 25-OH Vitamin D

Vitamin D and vitamin K2 work in a complementary way in bone metabolism. Vitamin D stimulates osteocalcin gene expression; vitamin K2 ensures that the resulting osteocalcin protein is fully carboxylated and functional [20]. A 25-OH vitamin D below 30 ng/mL combined with PIVKA-II above 2.0 ng/mL represents a dual-deficiency state that may blunt the expected bone response to either intervention used alone.

PIVKA-II in Hepatocellular Carcinoma Screening

PIVKA-II (also called DCP, des-gamma-carboxyprothrombin) is an established tumor marker for hepatocellular carcinoma (HCC), used at cutoffs of 40 mAU/mL or higher in the oncology context [21]. This is a distinct clinical application from the vitamin K sufficiency context described throughout this article. When PIVKA-II is ordered specifically as a vitamin K functional test and returns modestly elevated (2.0 to 7.0 ng/mL), liver disease rather than HCC is far more likely to be the explanation in primary-care settings, but an ALT/AST and hepatitis panel should accompany any unexplained elevation above 5.0 ng/mL.

Monitoring Schedule After Treatment Changes

Recheck timing depends on the intervention:

• Dietary change only: retest at 8 weeks.
• MK-7 180 mcg/day added: retest at 6 weeks.
• MK-7 360 mcg/day added (Tier 3): retest at 4 weeks.
• Warfarin dose adjusted: retest INR at 1 week; retest PIVKA-II at 4 weeks to confirm stable carboxylation status.
• GLP-1 or bariatric intervention: full fat-soluble vitamin panel including PIVKA-II at 6 months, then annually.

A PIVKA-II that fails to normalize after 8 weeks of MK-7 360 mcg/day warrants a malabsorption workup before further supplementation escalation [6].